264 related articles for article (PubMed ID: 17545756)
41. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism.
de Lange J; van Maarle MC; van den Akker HP; Redeker EJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):378-81. PubMed ID: 17321449
[No Abstract] [Full Text] [Related]
42. SH3BP2-related fibro-osseous disorders of the maxilla and mandible: A systematic review.
Kueper J; Tsimbal C; Olsen BR; Kaban L; Liao EC
Int J Oral Maxillofac Surg; 2022 Jan; 51(1):54-61. PubMed ID: 33941395
[TBL] [Abstract][Full Text] [Related]
43. A novel mutation in the SH3BP2 gene causes cherubism: case report.
Li CY; Yu SF
BMC Med Genet; 2006 Dec; 7():84. PubMed ID: 17147794
[TBL] [Abstract][Full Text] [Related]
44. Multiple versus solitary giant cell lesions of the jaw: Similar or distinct entities?
Schreuder WH; van der Wal JE; de Lange J; van den Berg H
Bone; 2021 Aug; 149():115935. PubMed ID: 33771761
[TBL] [Abstract][Full Text] [Related]
45. Giant cell reparative granuloma of the orbit associated with cherubism.
Font RL; Blanco G; Soparkar CN; Patrinely JR; Ostrowski ML
Ophthalmology; 2003 Sep; 110(9):1846-9. PubMed ID: 13129888
[TBL] [Abstract][Full Text] [Related]
46. [A case of familially associated cherubism, centro-osseous giant cell granulomas and giant cell tumors of the jaws].
Wechsler J; Grellet M
Rev Stomatol Chir Maxillofac; 1984; 85(4):337-40. PubMed ID: 6593801
[TBL] [Abstract][Full Text] [Related]
47. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.
Aliprantis AO; Ueki Y; Sulyanto R; Park A; Sigrist KS; Sharma SM; Ostrowski MC; Olsen BR; Glimcher LH
J Clin Invest; 2008 Nov; 118(11):3775-89. PubMed ID: 18846253
[TBL] [Abstract][Full Text] [Related]
48. Cherubism: a systematic literature review of clinical and molecular aspects.
Chrcanovic BR; Guimarães LM; Gomes CC; Gomez RS
Int J Oral Maxillofac Surg; 2021 Jan; 50(1):43-53. PubMed ID: 32620450
[TBL] [Abstract][Full Text] [Related]
49. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
50. [Genetic aspects of cherubism].
Brix M; Peters H; Ranfaing E; Ricbourg B
Rev Stomatol Chir Maxillofac; 2006 Apr; 107(2):105-8. PubMed ID: 16738517
[TBL] [Abstract][Full Text] [Related]
51. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
52. [Cherubism: regression of the lesions and spontaneous bone regeneration].
Timosca GC
Rev Stomatol Chir Maxillofac; 1996; 97(3):172-7. PubMed ID: 8711332
[TBL] [Abstract][Full Text] [Related]
53. Cherubism: best clinical practice.
Papadaki ME; Lietman SA; Levine MA; Olsen BR; Kaban LB; Reichenberger EJ
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S6. PubMed ID: 22640403
[TBL] [Abstract][Full Text] [Related]
54. Giant cell tumors of bone.
Roux S
Rev Rhum Engl Ed; 1998 Feb; 65(2):139-47. PubMed ID: 9540123
[TBL] [Abstract][Full Text] [Related]
55. Cherubism as a systemic skeletal disease: evidence from an aggressive case.
Morice A; Joly A; Ricquebourg M; Maruani G; Durand E; Galmiche L; Amiel J; Vial Y; Cavé H; Belhous K; Piketty M; Cohen-Solal M; Berdal A; Collet C; Picard A; Coudert AE; Kadlub N
BMC Musculoskelet Disord; 2020 Aug; 21(1):564. PubMed ID: 32825821
[TBL] [Abstract][Full Text] [Related]
56. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
57. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome.
Hanna N; Parfait B; Talaat IM; Vidaud M; Elsedfy HH
Clin Genet; 2009 Jun; 75(6):568-71. PubMed ID: 19438935
[TBL] [Abstract][Full Text] [Related]
58. Metatarsal giant cell tumors and giant cell reparative granuloma are similar entities.
Gouin F; Grimaud E; Redini F; Moreau A; Passuti N; Heymann D
Clin Orthop Relat Res; 2003 Nov; (416):278-84. PubMed ID: 14646771
[TBL] [Abstract][Full Text] [Related]
59. Novel karyotypes in giant cell-rich lesions of bone.
Gleason BC; Kleinman PK; Debelenko LV; Rahbar R; Gebhardt MC; Perez-Atayde AR
Am J Surg Pathol; 2007 Jun; 31(6):926-32. PubMed ID: 17527082
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
